2010
DOI: 10.1186/1477-9560-8-9
|View full text |Cite
|
Sign up to set email alerts
|

Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry

Abstract: BackgroundPoor platelet inhibition by aspirin or clopidogrel has been associated with adverse outcomes in patients with cardiovascular diseases. A reliable and facile assay to measure platelet inhibition after treatment with aspirin and a P2Y12 antagonist is lacking. Multiple electrode aggregometry (MEA), which is being increasingly used in clinical studies, is sensitive to platelet inhibition by aspirin and clopidogrel, but a critical evaluation of MEA monitoring of dual anti-platelet therapy with aspirin and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
20
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(22 citation statements)
references
References 28 publications
2
20
0
Order By: Relevance
“…In contrast, in patients with PAD, discrepant fi ndings about the clinical implications of platelet response to P2Y 12 receptor inhibition have been published [5,6]. Restenosis at the site of intervention is a great challenge in PAD as compared to CAD patients, and diff erences in vessel structures, diameters, rheological conditions and interventional techniques may account for a distinct role of HPR on clinical outcomes in PAD as compared to CAD patients.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…In contrast, in patients with PAD, discrepant fi ndings about the clinical implications of platelet response to P2Y 12 receptor inhibition have been published [5,6]. Restenosis at the site of intervention is a great challenge in PAD as compared to CAD patients, and diff erences in vessel structures, diameters, rheological conditions and interventional techniques may account for a distinct role of HPR on clinical outcomes in PAD as compared to CAD patients.…”
Section: Discussionmentioning
confidence: 99%
“…Platelet function data acquired using a Multiplate analyzer (Roche Diagnostics, Switzerland) as previously described [12] were entered into clinical practice in our centers in December 2008. For this cohort analysis, we retrospectively investigated patients with PAD and available peri-interventional adenosine diphosphate-(ADP-) induced platelet aggregation values after treatment with clopidogrel who underwent a successful pelvic or infrainguinal peripheral endovascular procedure in two participating centers (I. Medizinische Klinik, Klinikum rechts der Isar and Deutsches Herzzentrum München, Munich, Germany) between December 2008 and March 2013.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…In order to maximize the effectiveness of therapy and simultaneously minimalize the hazard of bleeding, DAPT should be tailored individually to each patient. MEA can be successfully used to assess the influence of aspirin (ASA) and P2Y 12 --receptor antagonists to platelet functions [11]. These two groups of drugs have an impact on platelet activity using different pathways.…”
Section: Clinical Use Of Mea In Cardiologymentioning
confidence: 99%